Special Issue

Metabolic Dysregulation in Fatty Liver Disease

Message from the Guest Editors

Fatty liver disease (FLD) is a growing global health crisis, associated with high morbidity, mortality, and significant economic burden. The disease is driven by insulin resistance, oxidative stress, and inflammation, leading to disrupted lipid and glucose metabolism.

This Special Issue focuses on the metabolic dysregulation underlying FLD and explores the disease's connections to other metabolic disorders. By bringing together multidisciplinary research, the Issue aims to advance the molecular understanding of FLD, identify novel biomarkers, and uncover new therapeutic targets.

This collection offers valuable insights for researchers, clinicians, and public health experts interested in the far-reaching impacts of metabolic dysregulation in FLD, while also pointing towards promising strategies for prevention and treatment.

Guest Editors

Dr. Ambrin Farizah Babu

School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70200 Kuopio, Finland

Prof. Dr. Youfei Guan

Advanced Institute of Medical Sciences, Dalian Medical University, Dalian 116044, China

Deadline for manuscript submissions

31 January 2026

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/219790

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).